Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Durata Therapeutics, Inc. | d405378d8k.htm |
Exhibit 99.1
DURATA THERAPEUTICS, INC. REPORTS SECOND QUARTER 2012 FINANCIAL AND CORPORATE RESULTS
MORRISTOWN, NJ, September 4, 2012 – Durata Therapeutics, Inc. (NASDAQ: DRTX), a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses, today announced financial and corporate results for the quarter ended June 30, 2012.
“We are pleased with the rate of patient enrollment in our ongoing Phase 3 clinical trials for our lead product candidate, dalbavancin, and continue to anticipate submitting a New Drug Application with the U.S. Food and Drug Administration in the first half of 2013,” said Paul Edick, Chief Executive Officer of Durata Therapeutics, Inc. “As anticipated, our research and development costs have increased substantially over the prior year period as we move towards completion of our Phase 3 clinical trials.”
Recent Accomplishments
Our significant recent accomplishments include the following:
| • | Completed our initial public offering, resulting in approximately $73.9 million of net proceeds, after deducting underwriting discounts and commissions, or approximately $71.4 million after the payment of $2.5 million of other offering expenses payable by us. |
| • | Progressed our ongoing Phase 3 clinical trials for our lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or abSSSI. |
| • | Passed the 60% enrollment level needed for our independent data monitoring committee, or DMC, interim analysis of the pooled and blinded early response rate and patient enrollment needed to maintain our 90% power calculation in each of our ongoing Phase 3 clinical trials. In the first trial, the DMC analysis indicated that we did not need to increase our enrollment target. In the analysis of the second trial, the DMC recommendation was to add 184 patients to our enrollment target. Based on our current enrollment rate, we do not expect this to cause any change in our previously disclosed timing of data availability or New Drug Application filing. |
| • | Added Lisa Giles, CEO & President of Giles & Associates and former Vice President of Strategy and Development at G.D. Searle & Company, as an independent director, effective August 3, 2012. |
Financial results for the quarter ended June 30, 2012
As of June 30, 2012, we had cash and cash equivalents of $12.4 million compared to $11.5 million at December 31, 2011. As previously stated, we closed on our initial public offering in July 2012 and raised $73.9 million in net proceeds.
Net loss for the three months ended June 30, 2012 (the “2012 Quarter”) was $19.2 million compared to net loss of $11.5 million for the three months ended June 30, 2011 (the “2011 Quarter”).
Research and Development expense for the 2012 Quarter was $16.5 million compared to $8.4 million for the 2011 Quarter. The $8.1 million increase from the 2011 Quarter to the 2012 Quarter principally resulted from an increase of $7.1 million in contract research organization and other clinical trial expenses, including consulting; an increase of $0.5 million for personnel costs to support our studies; and an increase of $0.5 million related to chemistry, manufacturing and control related expenses.
General and Administrative expense for the 2012 Quarter was $2.4 million compared to $1.3 million for the 2011 Quarter. The $1.1 million increase from the 2011 Quarter to the 2012 Quarter principally resulted from an increase of $0.6 million for personnel costs to support our pre-launch activities and an increase of $0.5 million in legal and consulting fees.
About Durata Therapeutics
Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata is currently enrolling and dosing patients in two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or abSSSI. For more information please visit www.duratatherapeutics.com.
Durata Safe Harbor Statement
Statements contained in this press release contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward looking statements in this press release include statements about the filing of a New Drug Application with the U.S. Food and Drug Administration. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the “Risk Factors” section of the prospectus for our recently completed initial public offering, which is on file with the SEC and is also available on our website. In addition, any forward-looking statements represent our views only as of today and
should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.
Media Relations Contact
Jed Weiner
White Oak Communications, Inc.
(847) 392-4186
jed.weiner@comcast.net
or
Investor Relations Contacts
Corey Fishman
Durata Therapeutics
Chief Operating Officer and Chief Financial Officer
(973) 993-4865
cfishman@duratatherapeutics.com
or
Lee M. Stern
The Trout Group LLC
(646) 378-2922
lstern@troutgroup.com
www.troutgroup.com
DURATA THERAPEUTICS, INC. AND SUBSIDIARY
(A Development Stage Company)
Condensed Consolidated Balance Sheet
Unaudited
(in thousands)
| December 31, 2011 |
June 30, 2012 |
|||||||
| Assets | ||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 11,485 | $ | 12,356 | ||||
| Prepaid expenses and other current assets |
997 | 904 | ||||||
|
|
|
|
|
|||||
| Total current assets |
12,482 | 13,260 | ||||||
| Acquired in process research and development |
15,292 | 15,292 | ||||||
| Goodwill |
5,811 | 5,811 | ||||||
| Restricted cash |
— | 500 | ||||||
| Deferred charge |
— | 10,991 | ||||||
| Deferred offering costs |
— | 1,499 | ||||||
| Other assets |
40 | 48 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 33,625 | $ | 47,401 | ||||
|
|
|
|
|
|||||
| Liabilities, Redeemable Preferred Stock and Stockholders’ Equity | ||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 1,957 | $ | 5,592 | ||||
| Accrued expenses |
1,369 | 4,700 | ||||||
| Income taxes payable |
— | 9,991 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
3,326 | 20,283 | ||||||
|
|
|
|
|
|||||
| Non-current income tax payable |
— | 1,000 | ||||||
| Contingent consideration |
18,739 | 19,279 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
22,065 | 40,562 | ||||||
|
|
|
|
|
|||||
| Redeemable portion - Series A Convertible Preferred Stock |
6,000 | 6,000 | ||||||
|
|
|
|
|
|||||
| Total stockholders’ equity |
5,560 | 839 | ||||||
|
|
|
|
|
|||||
| Total liabilities, redeemable preferred stock and stockholders’ equity |
$ | 33,625 | $ | 47,401 | ||||
|
|
|
|
|
|||||
DURATA THERAPEUTICS, INC. AND SUBSIDIARY
(A Development Stage Company)
Consolidated Statement of Operations
(Unaudited)
(in thousands, except share and per share data)
| Three Month Period Ended June 30, | Six Month Period Ended June 30, | Period from inception (November 4, 2009) to June 30, |
||||||||||||||||||
| 2011 | 2012 | 2011 | 2012 | 2012 | ||||||||||||||||
| Operating expenses: |
||||||||||||||||||||
| Research and development expenses |
$ | 8,439 | $ | 16,528 | $ | 12,768 | $ | 23,299 | $ | 58,448 | ||||||||||
| General and administrative expenses |
1,253 | 2,392 | 2,304 | 3,613 | 11,608 | |||||||||||||||
| Acquisition related charges, net |
2,376 | 272 | (403 | ) | 540 | 7,987 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Operating loss |
12,068 | 19,192 | 14,669 | 27,452 | 78,043 | |||||||||||||||
| Interest income |
(5 | ) | (4 | ) | (9 | ) | (7 | ) | (25 | ) | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Loss before income tax benefit |
12,063 | 19,188 | 14,660 | 27,445 | 78,018 | |||||||||||||||
| Income tax benefit |
(606 | ) | — | (782 | ) | — | (5,811 | ) | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Net loss |
$ | (11,457 | ) | $ | (19,188 | ) | $ | (13,878 | ) | $ | (27,445 | ) | $ | (72,207 | ) | |||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Net loss attributable to common stockholders |
$ | (11,457 | ) | $ | (19,188 | ) | $ | (13,878 | ) | $ | (27,445 | ) | $ | (72,207 | ) | |||||
| Net income attributable to Series A preferred stockholders |
— | — | — | — | — | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Net loss |
$ | (11,457 | ) | $ | (19,188 | ) | $ | (13,878 | ) | $ | (27,445 | ) | $ | (72,207 | ) | |||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Net loss per common share – Basic and Diluted |
$ | (183.31 | ) | $ | (260.25 | ) | $ | (242.23 | ) | $ | (402.94 | ) | ||||||||
| Weighted-average common shares – Basic and Diluted |
62,500 | 73,727 | 57,292 | 68,113 | ||||||||||||||||